Skip to main content

Table 3 Conductance catheterization

From: Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction

 

sham + vehicle

sham + dapa

sham + T-1095

MI + vehicle

MI + dapa

MI + T-1095

N

5

6

4

20

13

13

EDP (mmHg)

11 ± 2

12 ± 1

16 ± 2*

18 ± 1*

19 ± 1*

26 ± 2*

Pes (mmHg)

117 ± 11

127 ± 7

127 ± 15

107 ± 5

105 ± 5

95 ± 5*

HR (bpm)

296 ± 12

288 ± 12

299 ± 11

270 ± 7*

258 ± 6*

260 ± 9*

dP/dtmax (mmHg/s)

7031 ± 426

7471 ± 514

7815 ± 504

5443 ± 305*

5141 ± 249*

4201 ± 264*†‡

dP/dtmin (mmHg/s)

− 7190 ± 631

− 7922 ± 637

− 8927 ± 906*

− 4318 ± 260*

− 4192 ± 224*

− 3290 ± 246*†‡

EDPVR (mmHg/ml)

0.024 ± 0.004

0.025 ± 0.002

0.03 ± 0.01

0.06 ± 0.01

0.05 ± 0.01

0.10 ± 0.02*†‡

Tau (ms)

12.5 ± 0.6

12.6 ± 0.8

12.5 ± 0.7

17.5 ± 0.6*

18.0 ± 0.5*

23.2 ± 1.6*†‡

  1. EDP end-diastolic pressure, Pes end-systolic pressure, HR heart rate, EDPVR end-diastolic pressure volume relationship, ESPVR end-systolic pressure volume relationship
  2. * p < 0.05 vs. sham + vehicle group;  p < 0.05 vs. MI + vehicle group;  p < 0.05 vs. MI + dapagliflozin group